Proprotein convertase subtilisin/kexin type 9; proprotein convertase subtilisin/kexin type 9; Convertase subtilisin/kexin type 9 preproprotein antibody; FH3 antibody; HCHOLA3 antibody; Hypercholesterolemia autosomal dominant 3 antibody; LDLCQ1 antibody; NARC 1 antibody; NARC-1 antibody; NARC1 antibody; Neural apoptosis regulated convertase 1 antibody; Neural apoptosis-regulated convertase 1 antibody; PC 9 antibody; PC9 antibody; PCSK 9 antibody; PCSK9 antibody; PCSK9_HUMAN antibody; Proprotein convertase 9 antibody; Proprotein convertase PC9 antibody; Proprotein convertase subtilisin/kexin type 9 antibody; PSEC0052 antibody; Subtilisin/kexin like protease PC9 antibody; Subtilisin/kexin-like protease PC9 antibody

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Immunogen affinity purified.

Lyophilized

At -20 degree C for one year. After reconstitution, at 4 degree C for one month. It can also be aliquotted and stored frozen at -20 degree C for a longer time. Avoid repeated freezing and thawing.

Manufactured in an ISO 13485:2003 and EN ISO 13485:2012 Certified Laboratory.

Small volumes of anti-PCSK9 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Description: Rabbit IgG polyclonal antibody for Proprotein convertase subtilisin/kexin type 9(PCSK9) detection. Tested with WB, IHC-P in Human.
Background: Proprotein convertase subtilisin/kexin type 9, also known as PCSK9, is an enzyme that in humans is encoded by the PCSK9 gene. This gene encodes a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. By genomic sequence analysis, PCSK9 was mapped to chromosome 1p32. This gene is a crucial player in the regulation of plasma cholesterol homeostasis. It may prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. PCSK9 can induce ubiquitination of LDLR leading to its subsequent degradation. This gene is involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway.

Western Blot (WB), Immunohistochemistry (IHC) Paraffin

Anti-PCSK9 antibody, MBS176261, Western blotting
All lanes: Anti PCSK9 (MBS176261) at 0.5ug/ml
Lane 1: A549 Whole Cell Lysate at 40ug
Lane 2: HELA Whole Cell Lysate at 40ug
Lane 3: U87 Whole Cell Lysate at 40ug
Lane 4: PANC Whole Cell Lysate at 40ug
Predicted bind size: 74KD
Observed bind size: 74KD

Anti-PCSK9 antibody, MBS176261, IHC(P)
IHC(P): Human Intestinal Cancer Tissue

20,827 Da

proprotein convertase subtilisin/kexin type 9

proprotein convertase subtilisin/kexin type 9; subtilisin/kexin-like protease PC9; neural apoptosis regulated convertase 1; convertase subtilisin/kexin type 9 preproprotein

Proprotein convertase subtilisin/kexin type 9

NARC1; NARC-1; PC9??[Similar Products]

PCSK9_HUMAN

This gene encodes a member of the subtilisin-like proprotein convertase family, which includes proteases that process protein and peptide precursors trafficking through regulated or constitutive branches of the secretory pathway. The encoded protein undergoes an autocatalytic processing event with its prosegment in the ER and is constitutively secreted as an inactive protease into the extracellular matrix and trans-Golgi network. It is expressed in liver, intestine and kidney tissues and escorts specific receptors for lysosomal degradation. It plays a role in cholesterol and fatty acid metabolism. Mutations in this gene have been associated with autosomal dominant familial hypercholesterolemia. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2014]

PCSK9: Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways. Defects in PCSK9 are the cause of hypercholesterolemia autosomal dominant type 3 (HCHOLA3). A familial condition characterized by elevated circulating cholesterol contained in either low-density lipoproteins alone or also in very-low-density lipoproteins. Belongs to the peptidase S8 family. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Cell development/differentiation; Secreted; Protease; EC 3.4.21.-; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 1p32.3

Cellular Component: Golgi apparatus; extracellular space; extrinsic to external side of plasma membrane; cell surface; rough endoplasmic reticulum; endoplasmic reticulum; lysosome; perinuclear region of cytoplasm; early endosome; cytoplasm; late endosome; plasma membrane; ER to Golgi transport vesicle

Molecular Function: very-low-density lipoprotein binding; sodium channel inhibitor activity; protein binding; protein self-association; low-density lipoprotein receptor binding; serine-type endopeptidase activity; low-density lipoprotein binding; apolipoprotein binding; apolipoprotein receptor binding

Biological Process: cholesterol metabolic process; lysosomal transport; apoptosis; positive regulation of receptor internalization; lipoprotein metabolic process; regulation of low-density lipoprotein receptor catabolic process; cellular response to starvation; proteolysis; liver development; neuron differentiation; protein autoprocessing; cholesterol homeostasis; triacylglycerol metabolic process; neurogenesis; cellular response to insulin stimulus; phospholipid metabolic process; positive regulation of neuron apoptosis; regulation of neuron apoptosis; low-density lipoprotein receptor catabolic process; negative regulation of receptor recycling; regulation of receptor activity; kidney development

Disease: Hypercholesterolemia, Autosomal Dominant, 3

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.